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Abstract
Objective. Neuropathic symptoms are reported in
16–55.6% of patients with back pain. Studies were
performed in various populations; however, none
focused on older adults. The aim of the study was to
assess prevalence of neuropathic pain in older
adults with back pain.
Methods. Prevalence of neuropathic pain, mea-
sured with the Dolour Neuropathique en 4 questions
(DN4), was assessed in the Back Complaints in the
Elders study (Netherlands). Patients (>55 years)
consulting their general practitioner with a new
episode of back complaints were included. Two
DN4-versions were used: one based on interview
plus physical examination, the other based on inter-
view alone. In the interview plus physical examina-
tion version, patients’ and complaint characteristics
were compared between groups with different
scores (0, 1, 2, 3, and ≥4). The DN4 interview-version
compared patients with negative and positive
scores.
Results. Of the 261 included patients available for
analysis were 250 patients (95.8%) with the DN4
interview plus physical examination, and 259
patients (99.2%) with the DN4 interview. In DN4 inter-
view plus physical examination (N = 250), five
patients (2%) scored positive (score ≥4). Higher
score was associated with pain radiating below the
knee (P < 0.001) and use of paracetamol (P = 0.02). In
DN4 interview (N = 259), 29 (11.2%) patients scored
positive (score ≥3). Positive score was associated
with higher body mass index (P = 0.01), pain radiat-
ing below the knee (P = 0.001), and use of
paracetamol (P = 0.002).
Conclusions. In older adults with back pain pre-
senting with a new episode in primary care, preva-
lence of neuropathic pain is low and seems to be
associated with pain radiating below the knee, use
of paracetamol, and higher body mass index.
Key Words. Back Pain; Neuropathic Pain; Older
Adults
Introduction
Back pain is an important health problem in the commu-
nity [1–3], with the low back being the most affected area
[4]. A recent systematic review estimated the point preva-
lence of low back pain in the open population to be 11.9%
[3]. In older adults, benign or mild back pain seems to be
less frequent compared with other age groups, but they
experience more episodes with severe or disabling back
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pain [5]. Pain in older adults is reported to last longer
compared with younger patients with back pain [4]. With
the aging population, it is likely that a greater number of
people will suffer from severe back pain in the future.
Costs related to back pain are a substantial burden on
society [2,6]. As the prevalence of seeking health care for
back pain increases with age [2], costs will probably also
increase in the coming decades. It is noteworthy that
patients with neuropathic pain use more health care com-
pared with patients with nociceptive pain [7].
Neuropathic pain is defined as pain arising as a direct
consequence of a lesion or disease affecting the somato-
sensory system either at peripheral or central level [8]. In
back pain, although the mechanism of neuropathic pain is
not fully understood, most likely different mechanisms play
a role in the development of neuropathic pain. It is thought
that back pain can be a “mixed” pain consisting of noci-
ceptive and neuropathic components. Neuropathic pain
may be caused by lesions of nociceptive sprouts in the
degenerated intervertebral discs, by mechanical com-
pression of the nerve root or by action of inflammatory
mediators from degenerated intervertebral discs [9]. It is
important to identify patients with neuropathic pain and
neuropathic components because conventional analgesic
treatment may be less effective in this population [10–12].
Thus, identification of patients with neuropathic pain may
guide the choice of further investigation and/or therapy.
Various screening instruments are available to identify
neuropathic pain, such as Dolour Neuropathique en 4
questions (DN4) [13], Leeds Assessment of Neuropathic
Symptoms and Signs (LANSS) [14] and painDETECT [15].
These screening instruments have a sensitivity ranging
from 66–85% and specificity from 74–90% [13–18]. The
DN4 has shown good face validity and interrater reliability
in the general population, tested in persons with a mean
age of 56 years (standard deviation [SD] 17) [13], the
validity remained the same whether the patients had neu-
ropathic pain or mixed pain syndromes. The DN4 is also
validated in back pain patients aged 22–85 years of age.
Neuropathic symptoms are reported in 16–55.6% of
patients with low back pain, with and without radiating leg
pain [13,19–24]. The range is broad because studies were
performed in various populations. However, none of the
studies focused on older adults. In this cross-sectional
survey, we assessed the prevalence of neuropathic pain
using the DN4 in older adults who consulted their general
practitioner (GP) with a new episode of back complaints.
Furthermore, we compared two different DN4 versions
and evaluated whether differences exist in patients’ and
back complaint characteristics such as duration of back
pain and back pain severity between the groups with and
without neuropathic pain.
Methods
The present study included a subpopulation from the
Back Complaints in the Elders (BACE) study in the Neth-
erlands [25]. Patient inclusion in this Dutch BACE study
(N = 675) took place from March 2009 until September
2011. In BACE, patients aged >55 years were included
when they consult a GP with a new episode of back
complaints. Back complaints were defined as pain in at
least a part or the whole region from the top of the shoul-
der blades to the first sacral vertebra. If a patient had not
visited the GP with the same back complaints in the
preceding 6 months, it was considered a new episode.
Thus, the sample also included patients with longer dura-
tions of back pain who had not visited their GP in the
preceding 6 months for evaluation of this condition.
Patients were excluded if they were unable to fill out the
questionnaires due to cognitive impairment (e.g., demen-
tia or stroke) or were not able to read and write in Dutch.
Patients who were unable to undergo physical examina-
tion (e.g., wheelchair-bound patients) were also excluded.
For more details, see the design article of the BACE study
[25]. The subpopulation used in the present study con-
sisted of patients included from January 2011 onwards.
From this moment on, neuropathic pain was measured in
the participating patients during baseline measurement.
The Medical Ethics Committee of Erasmus Medical Center
in Rotterdam approved the study protocol.
Measurements
At the entry of this study, a baseline questionnaire was
completed by the patients and physical examination of the
back took place. The questionnaire included sociodemo-
graphic characteristics, patients self-reported comorbidity,
use of medication, and duration and localization of pain.
Severity of pain was measured on an 11-point numerical
rating scale (NRS) [26] with 0 as “no pain” and 10 repre-
senting “worst pain ever.” Disability was measured with the
Roland Morris Disability Questionnaire (RDQ) [27]. The
RDQ scores range from 0 (no disability) to 24 (severe
disability). Quality of life was measured with the Short-Form
36 (SF-36), Dutch version [28]. The SF-36 measures eight
dimensions: physical function, role-physical function,
bodily pain, general health, vitality, social function, role-
emotional function, and mental health. These eight dimen-
sions can be recoded into two summary scores: a physical
component summary score and a mental component
summary score. Each dimension and summary score is
scored from 1 to 100, with a higher score representing
better health [29,30]. Summary scores were calculated
with adapted Z-values, in view of the higher mean age of
our study population [28]. Depression was measured with
the Center for Epidemiologic Studies Depression Scale
(range 0–60). Patients with a higher score are more prone
to depression [31]. Pain catastrophizing was measured
with the pain catastrophizing scale (range 0–52), with a
higher score representing a higher risk for catastrophizing
[32]. Back beliefs were investigated with the back beliefs
questionnaire [33]. Lifestyle factors included smoking and
drinking alcohol. Drinking alcohol was measured with the
Audit-C [34,35]. Women were defined as possible hazard-
ous drinkers if they scored ≥3 on the scale, and men if they
scored ≥4. During physical examination, body weight and
height were measured and converted to body mass
index (BMI).
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For this substudy, we included those patients who com-
pleted both the DN4 interview plus physical examination.
The DN4 consists of a seven-item interview and a three-
item physical examination, with a score range of 0–10.
The interview consisted of questions about the pain char-
acteristics (burning, painful cold, electric shocks, tingling,
pins and needles sensation, numbness, and itchiness),
the physical examinations tested sensitivity to touch, pin-
prick, and brush. For a more detailed description of the
DN4, see Appendix A. In a general population, a score of
≥4 indicates neuropathic pain with a sensitivity of 83% and
a specificity of 90% [13]. The DN4 is validated in patients
with chronic low back pain in the age of 22–85 years [36]
and linguistically validated in Dutch [37]. The interview
(hereafter called the “DN4 interview”) can also be used
without the physical examination. In the DN4 interview, the
maximum score is 7 and a score of ≥3 indicates neuro-
pathic pain (sensitivity 82% and specificity 86%) [38].
Statistical Analysis
Descriptive statistics were used to present patient
characteristics in frequencies for all variables with
categorical data and to calculate mean and SD for con-
tinuous variables.
The DN4 interview plus physical examination, and the
DN4 interview alone, were analyzed separately. For the
DN4 interview plus physical examination, patients’ and
complaint characteristics were compared between all
groups with different scores (0, 1, 2, 3, and ≥4) with the
one-way analysis of variance for variables with numerical
data. Patients with a score of 4 and 5 were analyzed
together because of the small number of patients with
these scores. There were no patients with a score of 6 or
more. Groups were tested for equal variances using
Levene’s test, and a Kruskal–Wallis test was used if
assumptions for normality were not satisfied. Categorical
variables were analyzed with the chi-square test linear by
linear in which all groups with different scores were com-
pared. In the DN4 interview analysis, patients’ and com-
plaint characteristics were compared between patients
with a negative and a positive DN4 score using an inde-
pendent sample t-test. Levene’s test was used to test
equal variances; if assumptions for normality were not
satisfied, a Mann–Whitney U test was performed. Vari-
ables with categorical data were analyzed using the chi-
square test. If >20% of the cells contained an expected
count of <5, the tables were reduced. If the 2 × 2 table still
had an expected count <5, Fisher’s exact test was per-
formed. Reported P values were from two-sided tests,
and a P < 0.05 was defined as statistically significant. All
analyses were performed using SPSS software (version
17.0 for Windows, Chicago, IL, USA).
Results
The present study included 261 (38.7%) of the 675
patients from the Dutch BACE study. All patients
answered the DN4 questions, but two patients did not
answer all the questions in the interview. Nine patients did
not have a complete DN4 physical examination. There-
fore, 250 patients (95.8%) were available for the DN4
interview plus physical examination analysis, and 259
patients (99.2%) were available for analysis of the
DN4 interview.
Patients
Table 1 shows the baseline characteristics of the 261
included patients.
The mean age of the 261 patients was 66.4 ± 7.6 (range
56–87) years. Mean BMI was 27.7 ± 4.7. Of these
patients, 103 (39.5%) were male, 16.5% (43 patients)
smoke, and 122 patients (46.7%) were at risk for haz-
ardous drinking. Chronic back pain (pain lasting more
than 3 months) was present in 62 patients (23.8%), and
81 patients (31.0%) had pain radiating below the knee.
Mean baseline pain severity measured with the NRS was
5.0 ± 2.7. Of all patients, 184 (70.5%) used pain medi-
cation. The most frequently used were paracetamol
and nonsteroidal anti-inflammatory drugs. Mean time
between consulting a GP and DN4 measurement was
29.0 ± 12.8 days.
DN4 Interview Plus Physical Examination
Table 2 shows a comparison of patients’ and complaint
characteristics between the different scores of the 250
patients in the DN4 interview plus physical examina-
tion analysis.
Only five patients (2%) scored positive on the DN4 inter-
view plus physical examination (four patients scored 4;
one patient scored 5). There was significantly more pain
radiation in patients with a higher DN4 score. Patients
with a higher DN4 score also used significantly more
paracetamol. SF-36 physical summary score tended to be
lower in patients with a higher DN4 score, but the
difference was not significant.
DN4 Interview
Table 3 presents data on the comparison between
patients with positive and negative scores on the
DN4 interview.
In the DN4 interview, 111 patients (42.9%) scored 0
points, 85 patients (32.8%) scored 1 point, and 34
patients (13.1%) scored 2 points. A total of 25 patients
(9.7%) scored 3 points, three patients (1.2%) scored 4
points, and one patient (0.4%) scored 5 points. No
patients scored higher than 5 (total score range 0–7). Of
the 259 patients, 29 (11.2%) had a positive score (≥3
points) on the DN4 interview, which indicated neuropathic
pain. Patients having neuropathic pain had a significantly
higher BMI compared with patients who did not have
neuropathic pain. Patients with neuropathic pain more
often had pain radiating below the knee and use
paracetamol more frequently. Baseline back pain severity
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(NRS pain scale) was higher in neuropathic pain patients,
but the difference was not significant.
Discussion
Prevalence
In older adults with back pain, the prevalence of neuro-
pathic pain was 2% using the DN4 interview plus physical
examination and was 11.2% using the DN4 interview
alone. This is considerably lower than the 16–55.6%
reported by others [13,19–24]. There are various possible
reasons for this difference. First, most studies were per-
formed in specialist centers (mostly in secondary/tertiary
care) [13,19–22,24], whereas the present study was per-
formed in a primary care setting. Beith et al. analyzed
primary care patients with back pain who were referred for
physiotherapy, 95% of whom were referred by a GP [23];
they reported a neuropathic pain prevalence of 16% that is
more in line with our findings.
The screening tools used to measure neuropathic pain
may also explain the different prevalences. Different tools
including the DN4, LANSS [14], Self-Report LANSS
(S-LANSS) [18], and PainDETECT [15] were used. One
study compared S-LANSS and DN4 and obtained a dif-
ferent prevalence for patients with neuropathic pain using
these different screening tools [21]. This difference in
prevalence might be due to the absence of physical
examination in the S-LANSS, resulting in a lower preva-
lence (33 vs 42%). We found a higher prevalence in the
DN4 interview group. Physical examination in our study
was always performed on the spine. Another research
group recently suggested that physical examination as a
part of DN4 should also be performed on other painful
areas such as the leg [36]. This might also explain the
lower prevalence of our patients scoring positive on the
DN4 interview plus physical examination. On the other
hand, the tests performed in physical examination may not
be as sensitive in older adults.
A third difference is the duration of back pain. Most earlier
studies included patients if they had suffered back pain for
at least 3 months (chronic pain) [13,19,20,22,24], whereas
we included all patients with back pain irrespective of the
duration. In our population, mean duration ± SD of back
pain was 8.1 ± 31.9 months (median 1.1 month inter-
quartile range 0.7–3.3 months) (data not shown). In our
population, 23.8% of the patients had chronic back com-
plaints. It is possible that the neuropathic component of
back pain emerges after a longer period of back pain,
which might explain this difference in neuropathic
pain prevalence.
Interpretation of Findings
Use of paracetamol was more frequent in patients with
a positive neuropathic pain score. Torrance et al. [39]
reported that patients with neuropathic pain in primary
care took stronger painkillers, although they did not report
“over-the-counter” medications these people used. In the
present study, almost all patients were treated with con-
ventional analgesics rather than with antineuropathic
drugs; this is in line with the results from a Belgian study
[40]. Also, a rat study showed that paracetamol has
peripheral antiallodynic and antihyperalgesic effects [41],
mechanism that might contribute to pain relief in patients
with neuropathic pain. It is likely that patients with neuro-
pathic pain experience pain relief after taking paracetamol
and therefore continue to use them. On the other hand,
Table 1 Baseline patient characteristics of the
study population
All Patients
(N = 261)
Age in years 66.4 ± 7.6
Male, N (%) 103 (39.5)
BMI 27.7 ± 4.7
Low education level, N (%) 106 (40.6)
Smoking, N (%) 43 (16.5)
Hazardous drinking*, N (%) 122 (46.7)
Severity of back pain† 5.0 ± 2.7
Disability‡ 9.8 ± 5.7
Duration of back pain > 3 months, N (%) 62 (23.8)
Time in days between consultation with
general practitioner and the DN4
29.0 ± 12.8
Pain radiates to below the knee, N (%) 81 (31.0)
Pain location only lumbar, N (%) 188 (72.0)
Use of pain medication for back pain,
N (%):
184 (70.5)
Paracetamol, N (%) 100 (38.3)
NSAID, N (%) 97 (37.2)
Opioid, N (%) 22 (8.4)
Benzodiazepine, N (%) 16 (6.1)
Antidepressant or antiepileptic, N (%) 2 (0.8)
Diabetes, N (%) 41 (15.7)
Quality of life physical summary scale§ 43.7 ± 9.0
Quality of life mental summary scale§ 49.4 ± 10.2
Depressive symptomatology¶ 9.9 ± 7.8
Pain catastrophizing** 14.0 ± 11.0
Attitude and beliefs about back pain†† 26.4 ± 7.0
All results are presented as mean ± SD unless stated
otherwise.
* Hazardous drinking is measured with Audit-C: range 0–12; ≥3
in woman and ≥4 in men are risk of hazardous drinking.
† Measured with numerical rating scale; range 0–10; 0 is no
pain, 10 is the worst pain imaginable.
‡ Measured with the Roland Morris disability questionnaire
range 0–24; 0 is no disability.
§ Measured with Short-Form 36, range 0–100; higher score is
higher quality of life.
¶ Measured with CES-D, range 0–60; higher score indicates
more prone to depression.
** Measured with pain catastrophizing scale, range 0–52;
higher score is more risk for catastrophizing.
†† Measured with back beliefs questionnaire, range 9–49;
higher score is more positive thoughts of recovery.
BMI = body mass index; CES-D = Center for Epidemiologic
Studies Depression Scale; DN4 = Dolour Neuropathique
en 4 questions; NSAID = nonsteroidal anti-inflammatory drug;
SD = standard deviation.
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conventional analgesic treatment is also reported to be
less effective in neuropathic pain [10–12]. Patients might
also use more paracetamol because they did not experi-
ence sufficient pain relief.
In the present study, pain radiating below the knee was
associated with neuropathic pain, which is in line with
other reports [36,38] and with the belief that neuropathic
mechanisms play a greater role in leg pain than in
nonradiating back pain [15,24,42].
The physical summary score of the SF-36 tended to be
lower in patients with a higher score on the DN4, but the
difference was not significant. In the community, neuro-
pathic pain is associated with lower scores on all dimen-
sions of the SF-36 [7,43]. These results were also
observed in a study investigating primary care patients
[23]. Probably, our study was not sufficiently powered to
show significant difference between the groups.
Severity of back pain measured with the NRS tended to
be higher in patients with a positive DN4 score, but the
difference was not significant. Although some studies
reported an association between neuropathic pain and
pain severity [23,38,43–45], only one of these studies was
performed in back pain patients [23]. Another study
showed no association between neuropathic pain and
back pain severity [20]. It is possible that older adults
experience pain differently from younger persons, as dem-
onstrated in back pain [4,5]. Also, our lack of association
between pain severity and a positive score on the DN4
might be due to the small number of patients scoring
positive on the DN4.
We found no associations between neuropathic pain, and
age, gender, and duration of back pain. Recent literature
shows conflicting results concerning these characteristics.
Some data are in line with ours [20,40], whereas others
found associations with higher age [19,22,38,44] and
gender [19,22,38,44,45]. However, those studies were
performed in a general population or in secondary care,
while our study was performed in primary care. The
studies that found an association with age included a
younger group than ours, and their mean age remained
under 55 years; in view of the 10-year difference in mean
age, the effect they found may no longer present at older
age (55 years and over). Only Bouhassira et al. [38]
reported that neuropathic pain increases with age,
peaking at 50–64 years in a general population. It is pos-
sible that we found no association with age because our
patients were over 55 years of age and the age range of
our population was too small.
Table 2 Comparison of characteristics between scores of the DN4 interview and physical examination
(N = 250)
0 (N = 102) 1 (N = 82) 2 (N = 37) 3 (N = 24) >4 (N = 5) P Value
Age in years 67.0 ± 7.2 67.1 ± 8.5 64.7 ± 7.2 64.8 ± 7.0 62.8 ± 4.4 0.31
Male, N (%) 41 (40.2) 32 (39.0) 18 (48.6) 6 (25.0) 3 (60.0) 0.88
BMI* 27.3 ± 4.1 27.4 ± 4.5 28.2 ± 6.0 29.0 ± 4.2 33.2 ± 10.5 0.16
Low education level, N (%) 37 (36.6) 37 (46.3) 15 (40.5) 10 (41.7) 3 (60.0) 0.37
Smoking, N (%) 14 (13.9) 16 (20.0) 7 (18.9) 2 (8.7) 1 (20.0) 0.94
Hazardous drinking, N (%) 54 (54.5) 34 (43.6) 17 (45.9) 11 (47.8) 2 (40.0) 0.30
Severity of back pain 4.5 ± 2.7 5.0 ± 2.7 5.5 ± 2.7 5.9 ± 2.2 5.0 ± 3.1 0.15
Disability 8.9 ± 5.6 9.7 ± 5.9 11.1 ± 5.6 11.9 ± 5.1 10.6 ± 5.3 0.10
Duration of back pain > 3 months, N (%) 29 (30.9) 14 (19.2) 9 (25.7) 7 (33.3) 1 (20.0) 0.73
Time in days between consultation with
general practitioner and the DN4
28.4 ± 13.5 28.2 ± 12.0 28.4 ± 10.5 32.1 ± 16.3 28.0 ± 4.7 0.75
Pain radiates below the knee, N (%) 22 (21.8) 24 (30.0) 15 (40.5) 14 (58.3) 3 (60.0) <0.001
Pain location only lumbar 72 (70.6) 62 (75.6) 28 (75.7) 16 (66.7) 3 (60.0) 0.84
Use of paracetamol, N (%) 35 (34.7) 29 (36.3) 14 (37.8) 17 (70.8) 2 (40.0) 0.02
Use of NSAID, N (%) 39 (38.6) 28 (35.0) 17 (45.9) 8 (33.3) 1 (20.0) 0.75
Quality of life physical summary scale 45.2 ± 9.1 43.7 ± 8.7 40.8 ± 8.7 40.9 ± 8.3 42.0 ± 7.8 0.06
Quality of life mental summary scale 50.6 ± 9.9 48.8 ± 10.6 47.7 ± 10.6 48.2 ± 10.4 47.8 ± 9.3 0.54
Depressive symptomatology 8.8 ± 7.9 10.5 ± 7.6 12.3 ± 8.9 9.6 ± 6.6 13.8 ± 8.2 0.15
Pain catastrophizing 13.4 ± 10.7 13.8 ± 11.1 15.4 ± 11.3 15.9 ± 11.7 11.4 ± 12.3 0.48
Attitude and beliefs about back pain 26.8 ± 7.0 26.1 ± 6.7 24.9 ± 7.1 27.0 ± 7.3 22.8 ± 6.5 0.77
All results are presented as mean ± SD unless stated otherwise.
* Analyzed with the Kruskal–Wallis test.
BMI = body mass index; DN4 = Dolour Neuropathique en 4 questions; NSAID = nonsteroidal anti-inflammatory drug; SD = standard
deviation.
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Some studies reported an association between neuro-
pathic pain and the duration of pain [38,44], but was
not present in a study on patients with back pain
[36]. Also, we found no association between neuro-
pathic pain and duration of pain; however, this might be
because the studies that found an association were
performed in the general population. Also, in the
present study, older patients may not precisely recall
how long they experienced pain. However, to reduce
such recall bias, patients with cognitive problems
were excluded.
We also examined depression and disability because these
have also been associated with neuropathic pain [7,23,46].
However, other studies reported no difference in disability
and depression between patients with and without neuro-
pathic pain [21,47]. In our patients, although disability
tended to be higher in the positive group, the difference
was not significant and may be due to insufficient power.
Strength and Limitations
The present study evaluated neuropathic pain in older
adults reporting back pain in general practice. Other
studies analyzed neuropathic pain in older adults pooled
with patients of all ages. Our study provides additional
information about neuropathic pain specific to older
adults, which might be important because these patients
might experience pain differently [4,5].
We found a low prevalence of neuropathic pain
in older adults with back pain using two versions of the
DN4. Due to this low number of patients scoring
positive on the DN4, it is difficult to make statements
about the differences between patients with and
without neuropathic pain. Before we can make any
firm statements about the found associations in this
study, similar research should be performed in a larger
population of older adults. Statistical power of this
study would have increased if all patients of the Dutch
BACE cohort had filled in the DN4. However, because
we decided to include the DN4 measurement about
halfway through the inclusion period of the BACE-
study, less patients could be included. However,
because we continued to include consecutive patients
for this substudy, it is unlikely that we introduced
selection-bias. Furthermore, we analyzed multiple vari-
ables in a small population that could have led to find-
ings by chance.
Table 3 Comparison of patients scoring positive or negative on the DN4 interview
Characteristics
Negative DN4
(N = 230, 88.8%)
Positive DN4
(N = 29, 11.2%)
Mean Difference
(95% CI) P Value
Age in years 66.7 ± 7.7 64.4 ± 6.6 2.3 (−0.6–5.2) 0.13
Male, N (%) 93 (40.4) 9 (31.0) 0.33
BMI 27.4 ± 4.5 29.7 ± 5.8 −2.4 (−4.2–−0.5) 0.01
Low education, N (%) 93 (41.0) 13 (44.8) 0.87
Smoking* 40 (17.6) 3 (10.7) 0.44
Hazardous drinking, N (%) 108 (48.4) 13 (46.4) 0.84
Severity of back pain† 4.9 ± 2.7 5.7 ± 2.3 −0.9 (−1.9–0.17) 0.10
Disability 9.5 ± 5.8 11.7 ± 5.0 −2.1 (−4.4–0.1) 0.06
Duration of back pain > 3 months N (%) 54 (25.7) 8 (30.8) 0.58
Time in days between consultation with general
practitioner and the DN4
28.7 ± 12.5 31.4 ± 15.0 −2.8 (−7.7–2.2) 0.28
Pain radiates below the knee, N (%) 63 (27.8) 17 (58.6) 0.001
Pain location only lumbar, N (%) 169 (73.5) 19 (65.5) 0.09
Use of paracetamol, N (%) 81 (36.0) 19 (65.5) 0.002
Use of NSAID, N (%) 87 (38.7) 9 (31.0) 0.43
Quality of life physical summary scale 44.0 ± 9.1 41.1 ± 8.1 2.9 (−0.6–6.4) 0.10
Quality of life mental summary scale 49.5 ± 10.3 48.1 ± 10.1 1.4 (−2.5–5.4) 0.48
Depressive symptomatology 9.8 ± 7.9 10.4 ± 7.0 −0.5 (−3.6–2.6) 0.73
Pain catastrophizing 13.8 ± 10.9 15.1 ± 11.7 −1.2 (−5.6–3.1) 0.57
Attitude and beliefs about back pain 26.3 ± 6.9 26.2 ± 7.2 0.1 (−2.6–2.8) 0.94
All results are presented as mean ± SD unless stated otherwise. Bold values indicate a P-value <0.05.
* Analyzed using Fisher’s exact test.
† Analyzed using the Mann–Whitney U test.
BMI = body mass index; DN4 = Dolour Neuropathique en 4 questions; NSAID = nonsteroidal anti-inflammatory drug; SD = standard
deviation.
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It is thought that neuropathic pain is not just positive
or negative but can be more or less neuropathic [47–49].
This is why we analyzed all scores separately and
pooled patients scoring 4 or 5 on the DN4 interview
plus physical examination. Still most patients scored low
on the DN4. Because specific symptoms were examined
in DN4, this does not mean that their pain could
not have a neuropathic component, but it makes it
less likely.
Conclusions and Clinical Implications
This study shows a low prevalence of neuropathic pain in
older adults with a new episode of back pain (2% on the
DN4 interview plus physical examination and 11% on the
DN4 interview alone). Neuropathic pain seems to be asso-
ciated with pain radiating below the knee, increased use of
paracetamol, and higher BMI. Patients with neuropathic
pain could benefit from different treatment options.
Although the prevalence is low, it is important that
clinicians are aware of the possibility of neuropathic
pain in older adults with back pain presenting in gene-
ral practice.
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Appendix A
DN4 Questionnaire
Please complete this questionnaire by ticking one answer
for each item in the 4 questions below:
Interview of the Patient
Question 1: Does the pain have one or more of the fol-
lowing characteristics?
Yes No
Yes No
Yes No
Yes No
1 – Burning
2 – Painful cold
3 – Electric shocks
Question 2: Is the pain associated with one or more of the
following symptoms in the same area?
4 – Tingling
5 – Pins and needles
6 – Numbness
7 – Itching
Examination of the Patient
Question 3: Is the pain located in an area where the
physical examination may reveal one or more of the fol-
lowing characteristics?
8 – Hypoesthesia to touch
9 – Hypoesthesia to prick
Question 4: In the painful area, can the pain be caused or
increased by:
10 – Brushing
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